Ocular adnexal lymphoma – a retrospective study and review of the literature
, , e
15 set 2024
INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: Research Article
Pubblicato online: 15 set 2024
Pagine: 416 - 424
Ricevuto: 30 apr 2024
Accettato: 12 ago 2024
DOI: https://doi.org/10.2478/raon-2024-0048
Parole chiave
© 2024 Lucka Boltezar et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.

FIGURE 2.

FIGURE 3.

FIGURE 4.

Treatment outcome in 58 patients with post-treatment evaluation, post-treatment evaluation being done three to six months after the end of treatment
Complete remission | 46 (79.3%) |
Partial remission | 10 (17.2%) |
Stable disease | 1 (1.7%) |
Progressive disease | 1 (1.7%) |
Patients’ characteristics
30 (40.5%) | 44 (59.5%) | 74 | |
72 (range 41 – 89) | 67.5 (range 34 – 89) | 68 | |
- Marginal zone lymphoma (MALT) | 21/30 (70.0%) | 32/44 (72.7%) | 53/74 (71.6%) |
- Mantle cell lymphoma (MCL) | 6/30 (20.0%) | 3/44 (6.8%) | 9/74 (12.2%) |
- Follicular lymphoma (FL) | 2/30 (6.7%) | 4/44 (9.0%) | 6/74 (8.1%) |
- Diffuse large B-cell lymphoma (DLBCL) | 1/30 (3.3%) | 3/44 (6.8%) | 4/74 (5.4%) |
- Chronic lymphocytic leukemia (CLL) | 0/30 (0%) | 1/44 (2.3%) | 1/74 (1.4%) |
- Peripheral T-cell lymphoma, not otherwise specified | 0/30 (0%) | 1/44 (1.4%) | 1/74 (1.4%) |
7/30 (23.3%) | 11/44 (25.0%) | 18/74 (24.3%) | |
23/30 (76.7%) | 33/44 (75.0%) | 56/74 (75.7%) |
Specifications of orbital and conjunctival lymphomas
46/56 (82.1%) | 17/18 (94.4%) | 63/74 (85.1%) | |
10/56 (17.9%) | 1/18 (5.6%) | 11/74 (14.9%) | |
- Marginal zone lymphoma (MALT) | 36/56 (64.3%) | 17/18 (94.4%) | 53/74 (71.6%) |
- Mantle cell lymphoma (MCL) | 9/56 (16.1%) | 0/18 (0%) | 9/74 (12.2%) |
- Follicular lymphoma (FL) | 5/56 (8.9%) | 1/18 (5.6%) | 6/74 (8.1%) |
- Diffuse large B-cell lymphoma (DLBCL) | 4/56 (7.1%) | 0/18 (0%) | 4/74 (5.4%) |
- Chronic lymphocytic leukemia (CLL) | 1/56 (1.8%) | 0/18 (0%) | 1/74 (1.4%) |
- Peripheral T-cell lymphoma, not otherwise specified | 1/56 (1.8%) | 0/18 (0%) | 1/74 (1.4%) |